Taysha Gene Therapies (TSHA) Stock Forecast, Price & News

Taysha Gene Therapies (NASDAQ:TSHA) Frequently Asked Questions

Is Taysha Gene Therapies a buy right now?

14 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Taysha Gene Therapies in the last twelve months. There are currently 14 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Taysha Gene Therapies stock.
View analyst ratings for Taysha Gene Therapies or view top-rated stocks.

When is Taysha Gene Therapies' next earnings date?

Taysha Gene Therapies is scheduled to release its next quarterly earnings announcement on Monday, May 16th 2022.
View our earnings forecast for Taysha Gene Therapies.

How were Taysha Gene Therapies' earnings last quarter?

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) issued its quarterly earnings data on Thursday, March, 31st. The company reported ($1.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.21) by $0.11.
View Taysha Gene Therapies' earnings history.

What price target have analysts set for TSHA?

14 equities research analysts have issued 1 year target prices for Taysha Gene Therapies' shares. Their forecasts range from $25.00 to $44.00. On average, they expect Taysha Gene Therapies' stock price to reach $33.00 in the next year. This suggests a possible upside of 894.0% from the stock's current price.
View analysts' price targets for Taysha Gene Therapies or view top-rated stocks among Wall Street analysts.

Who are Taysha Gene Therapies' key executives?

Taysha Gene Therapies' management team includes the following people:

• Mr. R. A. Session II, Founder, Pres, CEO & Director (Age 43, Pay $634.63k) (LinkedIn Profile)
• Mr. Kamran Alam CPA, M.B.A., Chief Financial Officer (Age 44, Pay $756.38k) (LinkedIn Profile)
• Dr. Suyash Prasad FFPM, M.Sc., MBBS, M.D., M.B.B.S., F.F.P.M, Chief Medical Officer and Head of R&D (Age 52, Pay $501.78k)
• Dr. Claire Aldridge Ph.D., Sr. VP & Chief of Staff and Bus. Operations
• Mr. Frederick Porter Ph.D., Chief Technical Officer
• Mr. Jim Rouse, Chief Information Officer
• Mr. Timothy J. Douros J.D., Chief Legal Officer & Corp. Sec.
• Ms. Tracy M. Porter, Chief People Officer
• Ms. Emily McGinnis M.P.H., Chief Patient Officer & Head of Gov. Affairs
• Ms. Mishima Gerhart, Chief Regulatory Officer & Head of Quality

Who are some of Taysha Gene Therapies' key competitors?

Some companies that are related to Taysha Gene Therapies include Inhibrx (INBX), Century Therapeutics (IPSC), Atara Biotherapeutics (ATRA), Cullinan Oncology (CGEM), Aura Biosciences (AURA), Humacyte (HUMA), Mesoblast (MESO), Immunovant (IMVT), Ocugen (OCGN), Agenus (AGEN), Immatics (IMTX), Vaxart (VXRT), MeiraGTx (MGTX), ADMA Biologics (ADMA) and Outlook Therapeutics (OTLK).
View all of TSHA's competitors.

When did Taysha Gene Therapies IPO?

(TSHA) raised $125 million in an initial public offering (IPO) on Thursday, September 24th 2020. The company issued 6,600,000 shares at $18.00-$20.00 per share. Goldman Sachs, Morgan Stanley and Jefferies served as the underwriters for the IPO and Chardan was co-manager.

What is Taysha Gene Therapies' stock symbol?

Taysha Gene Therapies trades on the NASDAQ under the ticker symbol "TSHA."

Who are Taysha Gene Therapies' major shareholders?

Taysha Gene Therapies' stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (5.42%), Nantahala Capital Management LLC (3.30%), Vanguard Group Inc. (2.50%), TimesSquare Capital Management LLC (1.65%), State Street Corp (1.23%) and JPMorgan Chase & Co. (1.09%). Company insiders that own Taysha Gene Therapies stock include Kamran Alam, Paul B Manning, Phillip B Donenberg, RA Session II and Sean P Nolan.
View institutional ownership trends for Taysha Gene Therapies.

Which major investors are selling Taysha Gene Therapies stock?

TSHA stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Nantahala Capital Management LLC, and Northern Trust Corp.
View insider buying and selling activity for Taysha Gene Therapies or view top insider-selling stocks.

Which major investors are buying Taysha Gene Therapies stock?

TSHA stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, JPMorgan Chase & Co., Vanguard Group Inc., GSA Capital Partners LLP, Thompson Siegel & Walmsley LLC, State Street Corp, Nisa Investment Advisors LLC, and UBS Group AG. Company insiders that have bought Taysha Gene Therapies stock in the last two years include Paul B Manning, Phillip B Donenberg, RA Session II, and Sean P Nolan.
View insider buying and selling activity for Taysha Gene Therapies or or view top insider-buying stocks.

How do I buy shares of Taysha Gene Therapies?

Shares of TSHA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Taysha Gene Therapies' stock price today?

One share of TSHA stock can currently be purchased for approximately $3.32.

How much money does Taysha Gene Therapies make?

Taysha Gene Therapies has a market capitalization of $134.37 million. The company earns $-174.52 million in net income (profit) each year or ($4.630010) on an earnings per share basis.

How many employees does Taysha Gene Therapies have?

Taysha Gene Therapies employs 38 workers across the globe.

What is Taysha Gene Therapies' official website?

The official website for Taysha Gene Therapies is www.tayshagtx.com.

How can I contact Taysha Gene Therapies?

Taysha Gene Therapies' mailing address is 2280 Inwood Road, DALLAS TX, 75235. The company can be reached via phone at 214-612-0000 or via email at [email protected].